- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01048892
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To estimate the maximum-tolerated dose and/or recommended phase II dose of Seneca Valley virus-001 (NTX-010) when administered as a single infusion to pediatric patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features (Wilms tumor, retinoblastoma, adrenocortical carcinoma, or carcinoid tumors). (Part A [completed])
- To confirm that there is viral replication in these patients following NTX-010 administration. (Part A [completed])
- To define and describe the toxicities of NTX-010 when administered on this schedule. (Part A [completed])
- To determine whether the number of regulatory T cells (as measured by flow cytometry) can effectively be reduced following administration of NTX-010 plus low-dose metronomic and intravenous cyclophosphamide. (Part B)
- To characterize the pharmacokinetics (time course of viral clearance) following NTX-010 administration in these patients.
Secondary
- To preliminarily define the antitumor activity of NTX-010 within the confines of a phase I study. (Part A [completed])
- To evaluate the development of neutralizing antibodies to NTX-010 following IV administration of NTX-010. (Part A [completed])
- To evaluate development of neutralizing antibodies to NTX-010 following the combination of NTX-010 and cyclophosphamide. (Part B)
- To investigate the presence and permissivity of occult circulating tumor cells prior to and after the initial intravenous administration of NTX-010.
OUTLINE: This is a multicenter study.
Part A (completed): Patients receive Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
Part B: Patients receive cyclophosphamide IV orally (PO) on days 1-14 and NTX-010 IV over 1 hour on day 8. In the absence of disease progression or unacceptable toxicity, patients then receive cyclophosphamide orally (PO) on days 22-35, plus cyclophosphamide IV over 1 hour and NTX-010 IV over 1 hour on day 29.
Tumor tissue samples are collected at baseline for biomarker studies. Blood and stool samples are collected periodically for neutralizing antibody and viral clearance studies. Additional blood samples may also be collected for the presence and permissivity of occult tumor cells.
After completion of study treatment, patients are followed up periodically for up to 1 year.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Uab Comprehensive Cancer Center
-
-
California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
San Francisco, California, United States, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Children's Memorial Hospital - Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley's Children Cancer Center at Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, United States, 2115
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0286
- C.S. Mott Children's Hospital at University of Michigan Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
New York
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
-
Houston, Texas, United States, 77030-2399
- Baylor University Medical Center - Houston
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Midwest Children's Cancer Center at Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
- Neuroblastoma
- Rhabdomyosarcoma
- Wilms tumor
- Retinoblastoma
- Adrenocortical carcinoma
- Carcinoid tumor
- Relapsed or refractory disease
- Measurable or evaluable disease
- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life
- No known pulmonary tumors or metastases > 5 cm, as evaluated by chest CT scan
- No clinically significant pulmonary and/or pericardial effusions (≥ grade 3), as evaluated by ECHO
- No primary CNS tumors or known metastatic CNS disease involvement
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 50-100% (for patients > 16 years of age)
- Lansky PS 50-100% (for patients ≤ 16 years of age)
- Peripheral ANC ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3 (transfusion independent, defined as no platelet transfusions within a 7-day period before study enrollment)
- Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)
Creatine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows:
- ≤ 0.8 mg/dL (for patients 3 to 5 years of age)
- ≤ 1.0 mg/dL (for patients 6 to 9 years of age)
- ≤ 1.2 mg/dL (for patients 10 to 12 years of age)
- ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)
- ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)
- ≤ 1.7 mg/dL (for male patients ≥ 16 years of age)
- Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal (ULN)
- SGPT ≤ 110 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)
- Serum albumin ≥ 2 g/dL
- Oxygen saturation > 92% on room air
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to comply with the safety monitoring requirements of the study, in the opinion of the investigator
- Completely toilet trained
- No chronic diarrhea or urinary incontinence during the day or night, , and no in-dwellling urinary catheters
- No uncontrolled infection
- No known pregnant member of the household
PRIOR CONCURRENT THERAPY:
- Fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy
- At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
At least 3 months since prior stem cell transplantation or rescue (without TBI)
- No evidence of active graft-vs-host disease
- At least 6 weeks since other prior substantial bone marrow radiotherapy or treatment with therapeutic doses of MIBG
- More than 3 weeks since prior myelosuppressive chemotherapy
- At least 2 weeks since prior local palliative radiotherapy (small port)
- More than 7 days since prior growth factor(s) that support platelet or white blood cell number or function
- At least 7 days since prior biologic agents
- At least 3 half-lives since prior monoclonal antibodies
- More than 7 days since prior viral immunizations, including influenza
- At least 42 days since the completion of any type of immunotherapy, e.g., tumor vaccines
- No other viral immunizations after enrolling on study until 28 days after their last planned Seneca Valley virus-001 infusion or until documented viral clearance, whichever is longest
- Concurrent corticosteroids allowed provided the patient has been on a stable or decreasing dose for the past 7 days
- No other concurrent investigational drugs
- No other concurrent anticancer agents (e.g., chemotherapy, radiotherapy, immunotherapy, or biologic therapy)
- Prior treatment with Seneca Valley virus-001 is not allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (NTX-010)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability
Time Frame: 12 months post-documented viral clearance
|
12 months post-documented viral clearance
|
Recommended phase II dose of Seneca Valley virus-001 (NTX-010)
Time Frame: 56 days
|
56 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor response
Time Frame: Up to 12 months post documented viral clearance
|
Up to 12 months post documented viral clearance
|
Viral titers in blood and stool
Time Frame: Up to 56 days post treatment
|
Up to 56 days post treatment
|
Development of antibodies to NTX-010
Time Frame: Up to 4 weeks post treatment
|
Up to 4 weeks post treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Michael J. Burke, MD, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Endocrine System Diseases
- Retinal Diseases
- Endocrine Gland Neoplasms
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Eye Diseases, Hereditary
- Neuroendocrine Tumors
- Sarcoma
- Neuroectodermal Tumors, Primitive
- Neoplasms, Muscle Tissue
- Neuroectodermal Tumors, Primitive, Peripheral
- Eye Neoplasms
- Retinal Neoplasms
- Adrenal Gland Diseases
- Myosarcoma
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Neuroblastoma
- Retinoblastoma
- Rhabdomyosarcoma
- Carcinoid Tumor
- Adrenocortical Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
- ADVL0911
- COG-ADVL0911
- CDR0000663520 (Other Identifier: Clinical Trials.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted